Business Wire07.09.19
Kurin Inc., inventor and manufacturer of U.S. Food and Drug Administration (FDA)-cleared Kurin blood culture collection sets, has received CE Mark for the Kurin Lock.
“We are pleased to receive the CE Mark, the clearance needed for medical products to be marketed in this important region,” said Bob Rogers, CEO of Kurin. “The family of Kurin products was developed to help hospitals improve their blood culture samples and we look forward to helping hospitals in the EEA and EU Candidate States in their efforts to lower their contamination rates.”
Kurin developed initial specimen diversion technology that automatically and passively diverts potential contaminants during blood culture collection. Contaminated blood cultures are a significant problem, as roughly one-third of the positive results are wrong, exposing these patients to unnecessary antibiotics, extending hospital stays and impacting larger community health issues, such as antimicrobial resistance and the life-threatening C. diff. infection.
Kurin’s patented automatic blood diversion product is the only FDA 510k-cleared blood culture diversion product in the United States and now holds that same distinction for the European market.
Kurin Inc., a certified Minority Business Enterprise, is focused on the design, development, manufacture, marketing, and sale of products that help healthcare providers reduce contaminated blood cultures. Kurin products are manufactured in San Diego, Calif.
“We are pleased to receive the CE Mark, the clearance needed for medical products to be marketed in this important region,” said Bob Rogers, CEO of Kurin. “The family of Kurin products was developed to help hospitals improve their blood culture samples and we look forward to helping hospitals in the EEA and EU Candidate States in their efforts to lower their contamination rates.”
Kurin developed initial specimen diversion technology that automatically and passively diverts potential contaminants during blood culture collection. Contaminated blood cultures are a significant problem, as roughly one-third of the positive results are wrong, exposing these patients to unnecessary antibiotics, extending hospital stays and impacting larger community health issues, such as antimicrobial resistance and the life-threatening C. diff. infection.
Kurin’s patented automatic blood diversion product is the only FDA 510k-cleared blood culture diversion product in the United States and now holds that same distinction for the European market.
Kurin Inc., a certified Minority Business Enterprise, is focused on the design, development, manufacture, marketing, and sale of products that help healthcare providers reduce contaminated blood cultures. Kurin products are manufactured in San Diego, Calif.